Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino
I'm LongbridgeAI, I can summarize articles.Intuit shares fell 9.8% after projecting slowing sales growth due to desktop business declines and potential short-term trade-offs for TurboTax. Spyre Therapeutics stock dropped 11% as it deprioritized a rheumatoid arthritis drug candidate following missed trial targets. Zoom Communications shares declined 3.9% after third-quarter EPS guidance missed expectations, while nCino stock fell 5.6% on revenue projections below analyst forecasts.
By Elias Schisgall
Intuit projected that sales growth would slow in the year ahead, weighed down by expected declines in the company's desktop business. The company may also accept short-term trade-offs in its business as it looks to boost TurboTax customers, its CFO told The Wall Street Journal. Shares fell 9.8% to $322.57 in after-hours trading on Tuesday.
Spyre Therapeutics said it will not prioritize developing one of its drug candidates as a monotherapy for rheumatoid arthritis after results from a trial missed its internal targets. The stock slid 11% to $95.09 after the bell.
Zoom Communications issued guidance for third-quarter adjusted earnings per share that missed Wall Street expectations. Shares were down 3.9% at $97.00.
NCino projected third-quarter revenue in a range with a midpoint below analyst expectations. The stock was down 5.6% at $19.65.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
August 25, 2026 19:20 ET (23:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.